Morphic partners with investor AbbVie on integrin inhibitor development
The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.
The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.